Autologous Conditioned Plasma (ACP) Intra-articular (IA) Injections for Knee Osteoarthritis (OA)
- Conditions
- Osteoarthritis
- Interventions
- Other: PlaceboDevice: ACP
- Registration Number
- NCT02713542
- Lead Sponsor
- Arthrex, Inc.
- Brief Summary
This study is primarily investigating the effectiveness of Autologous Conditioned Plasma (ACP) Intra-articular (IA) in patients with Osteoarthritis (OA) in the knee.
- Detailed Description
This study is a prospective, multi center randomized double blind, two arm study.
90 subjects will be randomized to receive injections of either Autologous Conditioned Plasma Intra-articular or the control.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 90
- The subject is 18 to 70 years of age.
- The subject presents with complaints of continued pain of primary knee for at least 6 weeks.
- The subject has documented radiographs evidence of Osteoarthritis (OA) in the tibio-femoral or patella-femoral compartment of the target knee (Kellgren-Lawrence Grades II-III), using radiographs performed within 24 weeks of screening.
- The subject has a WOMAC pain score of at least 8 out of 20 and at least moderate pain (a score of 2) for at least 2 questions on activities
- Grade I and IV on the knee Kellgren-Lawrence grading scale
- Subject has clinically 3+ effusion of the target knee (stroke test grading system).
- Subject has significant (> 10⁰) valgus or varus deformities as evidenced by standard of care X-ray.
- Subject has had systemic or IA injection of corticosteroids in any joint within three months prior to screening.
- Viscosupplementation in any joint in the past six months.
- Subject has an increased risk for post- procedure bleeding (e.g., bleeding disorder or taking anticoagulants except low-dose aspirin).
- Subject had prior open surgery on the target knee within 12 months or knee arthroscopy within 6 months
- Subject has inflammatory disease of either knee other than OA.
- Subject with underlying medical conditions that could interfere with the evaluation of the outcome.
- Subject with positive pregnancy test, or breast feeding.
- Subject with plans to participate in other clinical trial involving medical or surgical intervention in the next 12 months.
- Subject with any condition (including cognitive impairment) that, in the opinion of the investigator, might interfere with the evaluation of the study objectives.
- Subject has rheumatoid arthritis or gout
- Subject has a history of or a current infection at the affected joint.
- Subject with plans to undergo any elective orthopedic surgery in the next 12 months.
- Subject requires pain management therapy (with the exception of acetaminophen) not related to the target knee.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Normal Saline (NS) Placebo 3 NS Intra-articular (IA) injections at 1 week intervals Autologous Conditioned Plasma (ACP) ACP 3 Intra-articular (IA) injections at 1 week intervals
- Primary Outcome Measures
Name Time Method Pain Scores Measured by Western Ontario and McMaster Universities Index (WOMAC) Survey 6 month visit The WOMAC Pain score will be used to measure outcome, the score ranges from 0 to 20. The higher the score indicates greater pain.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (4)
Rush University Medical Center
🇺🇸Chicago, Illinois, United States
MedSport University of Michigan Sports Medicine
🇺🇸Ann Arbor, Michigan, United States
Columbia Orthopedic Group
🇺🇸Columbia, Missouri, United States
Hawkins Foundation
🇺🇸Greenville, South Carolina, United States